| Dr Lucian J Introcaso, MD | |
|
9370 N Crescent Blvd Ste 200, Pennsauken, NJ 08110-1375 | |
| (856) 662-0660 | |
| Not Available |
| Full Name | Dr Lucian J Introcaso |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Preventive Medicine/occupational Environmental Medicine |
| Location | 9370 N Crescent Blvd Ste 200, Pennsauken, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386795680 | NPI | - | NPPES |
| Entity Name | American Current Care Of New Jersey Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609044999 PECOS PAC ID: 1153461264 Enrollment ID: O20091222000279 |
News Archive
GfK Healthcare's Roper Global Diabetes Programme, the definitive global perspective on diabetes, announced today the launch of its enhanced 2009/2010 Western Europe Patient Study. Offering a holistic perspective of the diabetes patient across five European countries, with robust insights into patients' attitudes and behaviors towards treatments, testing and lifestyles, the study now makes available to marketers greater reporting frequency and focus across a variety of broad-based and niche diabetes patient groups.
The University of New Mexico Cancer Center is among a few select institutions nationwide participating in a Phase 3 clinical trial studying a novel treatment for men with newly diagnosed, localized prostate cancer.
If one spouse exercises, quits smoking, stops drinking alcohol, receives a flu shot, or undergoes a cholesterol screening, the other spouse is more likely to do the same, according to a new study in Health Services Research.
Ocular Therapeutix, Inc. announced today initial results of their sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma. This travoprost punctum plug (OTX-TP1) was evaluated for the reduction of elevated intraocular pressure in subjects with open-angle glaucoma or ocular hypertension over a 30 day period.
Sales of Abstral continue to show robust growth, with royalty revenues rising sharply during the fourth quarter – up threefold from the preceding quarter. Our partner, ProStrakan, launched during 2009 Abstral in UK, Germany, France, Spain and Greece, and product launches in additional markets are imminent. Sales growth confirms that there is a substantial medical requirement in the case of cancer patients suffering from breakthrough pain.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lucian J Introcaso, MD 2 Crestmont Ln, Collingswood, NJ 08108-1487 Ph: (856) 662-0660 | Dr Lucian J Introcaso, MD 9370 N Crescent Blvd Ste 200, Pennsauken, NJ 08110-1375 Ph: (856) 662-0660 |
News Archive
GfK Healthcare's Roper Global Diabetes Programme, the definitive global perspective on diabetes, announced today the launch of its enhanced 2009/2010 Western Europe Patient Study. Offering a holistic perspective of the diabetes patient across five European countries, with robust insights into patients' attitudes and behaviors towards treatments, testing and lifestyles, the study now makes available to marketers greater reporting frequency and focus across a variety of broad-based and niche diabetes patient groups.
The University of New Mexico Cancer Center is among a few select institutions nationwide participating in a Phase 3 clinical trial studying a novel treatment for men with newly diagnosed, localized prostate cancer.
If one spouse exercises, quits smoking, stops drinking alcohol, receives a flu shot, or undergoes a cholesterol screening, the other spouse is more likely to do the same, according to a new study in Health Services Research.
Ocular Therapeutix, Inc. announced today initial results of their sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma. This travoprost punctum plug (OTX-TP1) was evaluated for the reduction of elevated intraocular pressure in subjects with open-angle glaucoma or ocular hypertension over a 30 day period.
Sales of Abstral continue to show robust growth, with royalty revenues rising sharply during the fourth quarter – up threefold from the preceding quarter. Our partner, ProStrakan, launched during 2009 Abstral in UK, Germany, France, Spain and Greece, and product launches in additional markets are imminent. Sales growth confirms that there is a substantial medical requirement in the case of cancer patients suffering from breakthrough pain.
› Verified 1 days ago